Kenox Pharmaceuticals is Empowered by Dr. Julianne Berry.

Innovation Process Begins at Kenox with New Appointment

Kenox Pharmaceuticals Inc. announced on October 21, 2025, the appointment of Dr. Julianne Berry as Vice President of Research and Development and Manufacturing. Dr. Berry will manage Kenox's integrated development, manufacturing, and testing operations and accelerate the company's innovative and efficient projects on inhalation, nasal, and eye drop drug-device combination products.

Dr. Berry has over 30 years of experience in the research, development, and commercialization of respiratory and specialty products in both U.S. and international markets. She has played a significant role in the success of many therapies launched to markets, including metered dose inhalers (MDIs), nasal sprays, dry powder inhalers, and nebulizers. Throughout her career, Dr. Berry has held senior leadership positions at companies such as Schering-Plough, Merck, Novel, Lupin, Glenmark, and Odin, and is recognized for her expertise in leading the development of respiratory drug delivery technologies.

Expressing her excitement about joining the Kenox team, Dr. Berry stated, "I am very excited to join an experienced and creative Kenox team that is committed to accelerating the development of an innovative pipeline of inhalation, nasal, and eye drop products. I look forward to helping these vital therapies reach the clinical setting faster, ensuring patients can access them as soon as possible."

Kenox Pharmaceuticals CEO Dr. Sitaram Velaga remarked, "We are thrilled to welcome Dr. Berry to Kenox. Her extensive expertise in respiratory and nasal product development, combined with her proven leadership, aligns perfectly with Kenox’s mission to deliver next-generation drug-device combination therapies with scientific rigor and operational excellence."

Dr. Berry's appointment stands out as another demonstration of Kenox's continued growth in supporting integrated research and development, filling-finish, and analytical services with drug and biotechnology partners worldwide.

About Kenox Pharmaceuticals

Kenox Pharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in inhalation, intranasal, and ophthalmic therapies. With fully integrated research and development, filling-finish, and analytical testing capabilities, Kenox accelerates the development and delivery of complex drug-device combination products by supporting pharmaceutical and biotechnology innovators from concept to clinic.